$\square$ 

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

| Check this box if no longer subject to<br>Section 16. Form 4 or Form 5<br>obligations may continue. See<br>Instruction 1(b). |
|--|
|  |

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| OMB APPRC               | VAL       |
|-------------------------|-----------|
| OMB Number:             | 3235-0287 |
| Estimated average burde | en        |
| hours per response:     | 0.5       |

| 1. Name and Address of Reporting Person <sup>*</sup><br>Berkenblit Anna |               |                | 2. Issuer Name and Ticker or Trading Symbol <u>IMMUNOGEN INC</u> [ IMGN ] | (Check                 | tionship of Reporting Perso<br>all applicable)<br>Director<br>Officer (give title           | son(s) to Issuer<br>10% Owner<br>Other (specify |  |
|---|---------------|----------------|---|------------------------|---|---|--|
| (Last)<br>C/O IMMUNOC<br>830 WINTER S                                   |               | (Middle)       | 3. Date of Earliest Transaction (Month/Day/Year)<br>10/16/2018            |                        | below)<br>VP & Chief Medica   | below)  |  |
| (Street)<br>WALTHAM<br>(City)   | MA<br>(State) | 02152<br>(Zip) | 4. If Amendment, Date of Original Filed (Month/Day/Year)                  | 6. Indiv<br>Line)<br>X | idual or Joint/Group Filing<br>Form filed by One Repor<br>Form filed by More than<br>Person | rting Person                                    |  |

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 3.<br>Transa<br>Code (l<br>8) |   |                      |   |                           | Securities<br>Beneficially         | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---------------------------------|--|---|-------------------------------|---|----------------------|---|---------------------------|------------------------------------|---|---|
|                                 |  |   | Code                          | v | Amount (A) or<br>(D) |   | Price                     | Transaction(s)<br>(Instr. 3 and 4) |   | (11311.4)   |
| Common Stock                    | 10/16/2018                                 |   | S                             |   | 5,851 <sup>(2)</sup> | D | <b>\$8</b> <sup>(1)</sup> | 132,769                            | D   |   |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   | 5. Number<br>of<br>Derivative<br>Securities<br>Acquired<br>(A) or<br>Disposed<br>of (D)<br>(Instr. 3, 4<br>and 5) |     | 6. Date Exerc<br>Expiration Da<br>(Month/Day/) | 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative<br>Security (Instr. 3<br>and 4) |       | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |  |
|---|---|--|---|------------------------------|---|---|-----|--|---|-------|---|--|--|--|--|
|   |   |  |   | Code                         | v | (A)   | (D) | Date<br>Exercisable                            | Expiration<br>Date  | Title | Amount<br>or<br>Number<br>of<br>Shares              |  |  |  |  |

**Explanation of Responses:** 

1. Weighted average price of shares sold.

2. The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan executed by the reporting person.

## /s/ Craig Barrows, attorney in

fact

10/17/2018

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.